News
All
News
Scientific Publications
Video
November 14, 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
Despite clinicians having a variety of therapeutic options for rheumatoid arthritis (RA), very few p…
Read more
November 1, 2024
Illuminating the Dark Genome to enable drug discovery from human genetics
The Dark Genome Symposium Heward J, Smith J, Owers L, Davidson B, James-Bott A, Repapi E, Hertweck A…
See Poster
November 1, 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
The Dark Genome Symposium Hargreaves C, Jozefowska W, Lucchesi D, Maio S, Hertweck A, Repapi E, Sutt…
See Poster
October 22, 2024
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
September 17, 2024
Biotech TV interview with CEO Mark Bodmer
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how…
Read more
July 16, 2024
Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
July 16, 2024
Nucleome Therapeutics announces transition of leadership
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
April 25, 2024
Nucleome Therapeutics establishes Scientific Advisory Board of world-leading experts and appoints Dr John Davis as Non-Executive Director of the Board
Newly founded SAB comprised of experts across dark genome genetics and drug discovery. Dr John Davis…
Read more
November 13, 2023
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer
Key appointment bringing 30 years of drug discovery and development expertise as the Company continu…
Read more
November 1, 2023
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
• Event brings together leading academics, industry representatives and investors to share progres…
Read more
September 28, 2023
Nucleome: linking ‘dark’ genome variants to drug targets via 3D DNA structures
Nucleome believes its high-resolution view into 3D genomic structures can pull actionable drug targe…
Read more
September 6, 2023
Nucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the Board
• Dr Greig brings more than 40 years of experience in the biopharmaceutical sector• Experienced …
Read more
April 3, 2023
Nucleome Therapeutics appoints Jonny Wray, Ph.D. as Senior Vice President of Data Science and Informatics
Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decodi…
Read more
October 19, 2022
New ‘Dark Genome’ Biotech Gets Backing From Big Pharma Venture Funds
New UK-based biotech Nucleome Therapeutics has gained backing from several big pharma venture funds …
Read more
October 19, 2022
Nucleome secures £37.5M to help illuminate non-coding gene functions
Nucleome Therapeutics Ltd. is poised to shed some light on the dark matter of the genome after raisi…
Read more
October 19, 2022
Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A
While the combo of machine learning and drug discovery has managed to rake in a lot of capital for c…
Read more
October 19, 2022
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome …
Read more
February 11, 2022
Nucleome Therapeutics Announces Formation of Advisory Board
Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome announce…
Read more
November 5, 2021
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
Study conducted by Nucleome’s academic founders from the University of Oxford published in Na…
Read more
November 1, 2021
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
NATURE GENETICS Downes DJ, Cross AR, Hua P, Roberts N, Schwessinger R, Cutler AJ, Munis AM, Brown J,…
Read more
October 7, 2021
Nature Biotechnology puts a spotlight on Nucleome’s innovative platform technology that mines the non-coding part of the genome, or ‘dark matter’, and discusses why this dark genome has huge potential for drug discovery
Scientists are using new tools to mine the non-coding part of the genome, known as ‘dark matter’…
Read more
July 20, 2021
Dr Danuta Jeziorska, CEO and co-founder of Nucleome Therapeutics explains how the Company is Shining a light on the dark genome in MedNous, Research Strategy article
July 1, 2021
Defining genome architecture at base-pair resolution
NATURE Hua P, Badat M, Hanssen LLP, Hentges LD, Crump N, Downes DJ, Jeziorska DM, Oudelaar AM, Schwe…
Read more
May 25, 2021
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
New method is being used by Nucleome to unlock the dark matter of the human genome for drug target d…
Read more
May 25, 2021
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
Nucleome’s unique technology platform has the potential to discover precision therapeutics across …
Read more
January 22, 2021
High-resolution targeted 3C interrogation of cis-regulatory element organization at genome-wide scale
NATURE COMMUNICATIONS Downes DJ, Beagrie RA, Gosden ME, Telenius J, Carpenter SJ, Nussbaum L, De Orn…
Read more
November 27, 2019
A revised model for promoter competition based on multi-way chromatin interactions at the α-globin locus
NATURE COMMUNICATION Oudelaar AM, Harrold CL, Hanssen LLP, Telenius JM, Higgs DR, Hughes JR. PMID: 3…
Read more
December 1, 2018
Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains
NATURE GENETICS Oudelaar AM, Davies JOJ, Hanssen LLP, Telenius JM, Schwessinger R, Liu Y, …
Read more
December 15, 2017
Robust detection of chromosomal interactions from small numbers of cells using low-input Capture-C
NUCLEIC ACIDS RESEARCH Oudelaar AM, Davies JOJ, Downes DJ, Higgs DR, Hughes JR. PMID: 29186505
Read more
December 5, 2017
Low-input Capture-C: A Chromosome Conformation Capture Assay to Analyze Chromatin Architecture in Small Numbers of Cells
BIO-PROTOCOL Oudelaar AM, Downes DJ, Davies JOJ, Hughes JR. PMID: 29270442
Read more
January 31, 2017
How best to identify chromosomal interactions: a comparison of approaches
NATURE METHODS Davies JO, Oudelaar AM, Higgs DR, Hughes JR. PMID: 28139673
Read more
November 23, 2015
Multiplexed analysis of chromosome conformation at vastly improved sensitivity
NATURE METHODS Davies JO, Telenius JM, McGowan SJ, Roberts NA, Taylor S, Higgs DR, Hughes JR. PMID: …
Read more
Page
1
2
3
4
News
November 14, 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
Despite clinicians having a variety of therapeutic options for rheumatoid arthritis (RA), very few p…
Read more
News
October 22, 2024
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
News
July 16, 2024
Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
News
July 16, 2024
Nucleome Therapeutics announces transition of leadership
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi…
Read more
News
April 25, 2024
Nucleome Therapeutics establishes Scientific Advisory Board of world-leading experts and appoints Dr John Davis as Non-Executive Director of the Board
Newly founded SAB comprised of experts across dark genome genetics and drug discovery. Dr John Davis…
Read more
News
November 13, 2023
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer
Key appointment bringing 30 years of drug discovery and development expertise as the Company continu…
Read more
News
November 1, 2023
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
• Event brings together leading academics, industry representatives and investors to share progres…
Read more
News
September 28, 2023
Nucleome: linking ‘dark’ genome variants to drug targets via 3D DNA structures
Nucleome believes its high-resolution view into 3D genomic structures can pull actionable drug targe…
Read more
News
September 6, 2023
Nucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the Board
• Dr Greig brings more than 40 years of experience in the biopharmaceutical sector• Experienced …
Read more
News
April 3, 2023
Nucleome Therapeutics appoints Jonny Wray, Ph.D. as Senior Vice President of Data Science and Informatics
Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decodi…
Read more
News
October 19, 2022
New ‘Dark Genome’ Biotech Gets Backing From Big Pharma Venture Funds
New UK-based biotech Nucleome Therapeutics has gained backing from several big pharma venture funds …
Read more
News
October 19, 2022
Nucleome secures £37.5M to help illuminate non-coding gene functions
Nucleome Therapeutics Ltd. is poised to shed some light on the dark matter of the genome after raisi…
Read more
News
October 19, 2022
Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A
While the combo of machine learning and drug discovery has managed to rake in a lot of capital for c…
Read more
News
October 19, 2022
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome …
Read more
News
February 11, 2022
Nucleome Therapeutics Announces Formation of Advisory Board
Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome announce…
Read more
News
November 5, 2021
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
Study conducted by Nucleome’s academic founders from the University of Oxford published in Na…
Read more
News
October 7, 2021
Nature Biotechnology puts a spotlight on Nucleome’s innovative platform technology that mines the non-coding part of the genome, or ‘dark matter’, and discusses why this dark genome has huge potential for drug discovery
Scientists are using new tools to mine the non-coding part of the genome, known as ‘dark matter’…
Read more
News
July 20, 2021
Dr Danuta Jeziorska, CEO and co-founder of Nucleome Therapeutics explains how the Company is Shining a light on the dark genome in MedNous, Research Strategy article
News
May 25, 2021
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
New method is being used by Nucleome to unlock the dark matter of the human genome for drug target d…
Read more
News
May 25, 2021
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
Nucleome’s unique technology platform has the potential to discover precision therapeutics across …
Read more
Page
1
2
3
Scientific Publications
November 1, 2024
Illuminating the Dark Genome to enable drug discovery from human genetics
The Dark Genome Symposium Heward J, Smith J, Owers L, Davidson B, James-Bott A, Repapi E, Hertweck A…
See Poster
Scientific Publications
November 1, 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
The Dark Genome Symposium Hargreaves C, Jozefowska W, Lucchesi D, Maio S, Hertweck A, Repapi E, Sutt…
See Poster
Scientific Publications
November 1, 2021
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
NATURE GENETICS Downes DJ, Cross AR, Hua P, Roberts N, Schwessinger R, Cutler AJ, Munis AM, Brown J,…
Read more
Scientific Publications
July 1, 2021
Defining genome architecture at base-pair resolution
NATURE Hua P, Badat M, Hanssen LLP, Hentges LD, Crump N, Downes DJ, Jeziorska DM, Oudelaar AM, Schwe…
Read more
Scientific Publications
January 22, 2021
High-resolution targeted 3C interrogation of cis-regulatory element organization at genome-wide scale
NATURE COMMUNICATIONS Downes DJ, Beagrie RA, Gosden ME, Telenius J, Carpenter SJ, Nussbaum L, De Orn…
Read more
Scientific Publications
November 27, 2019
A revised model for promoter competition based on multi-way chromatin interactions at the α-globin locus
NATURE COMMUNICATION Oudelaar AM, Harrold CL, Hanssen LLP, Telenius JM, Higgs DR, Hughes JR. PMID: 3…
Read more
Scientific Publications
December 1, 2018
Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains
NATURE GENETICS Oudelaar AM, Davies JOJ, Hanssen LLP, Telenius JM, Schwessinger R, Liu Y, …
Read more
Scientific Publications
December 15, 2017
Robust detection of chromosomal interactions from small numbers of cells using low-input Capture-C
NUCLEIC ACIDS RESEARCH Oudelaar AM, Davies JOJ, Downes DJ, Higgs DR, Hughes JR. PMID: 29186505
Read more
Scientific Publications
December 5, 2017
Low-input Capture-C: A Chromosome Conformation Capture Assay to Analyze Chromatin Architecture in Small Numbers of Cells
BIO-PROTOCOL Oudelaar AM, Downes DJ, Davies JOJ, Hughes JR. PMID: 29270442
Read more
Scientific Publications
January 31, 2017
How best to identify chromosomal interactions: a comparison of approaches
NATURE METHODS Davies JO, Oudelaar AM, Higgs DR, Hughes JR. PMID: 28139673
Read more
Scientific Publications
November 23, 2015
Multiplexed analysis of chromosome conformation at vastly improved sensitivity
NATURE METHODS Davies JO, Telenius JM, McGowan SJ, Roberts NA, Taylor S, Higgs DR, Hughes JR. PMID: …
Read more
Page
1
2
Video
September 17, 2024
Biotech TV interview with CEO Mark Bodmer
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how…
Read more
Decoding the Dark Genome
Read and watch how the dark genome regulates the expression of genes